Sigma Planning Corp Sells 1,340 Shares of Novo Nordisk A/S $NVO

Sigma Planning Corp cut its holdings in Novo Nordisk A/S (NYSE:NVO) by 11.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 10,053 shares of the company’s stock after selling 1,340 shares during the quarter. Sigma Planning Corp’s holdings in Novo Nordisk A/S were worth $694,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Stone House Investment Management LLC acquired a new position in shares of Novo Nordisk A/S in the first quarter valued at approximately $30,000. Disciplina Capital Management LLC lifted its position in Novo Nordisk A/S by 162.3% in the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after acquiring an additional 297 shares in the last quarter. Dagco Inc. acquired a new position in Novo Nordisk A/S in the 1st quarter worth $35,000. Mid American Wealth Advisory Group Inc. acquired a new position in Novo Nordisk A/S in the 2nd quarter worth $37,000. Finally, State of Wyoming bought a new position in Novo Nordisk A/S during the 1st quarter worth about $38,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $45.62 on Friday. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The company’s fifty day simple moving average is $55.32 and its 200 day simple moving average is $61.49. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $112.52. The company has a market cap of $203.69 billion, a price-to-earnings ratio of 12.53, a PEG ratio of 2.33 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. The firm had revenue of $11.74 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. On average, research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. TD Cowen cut their price target on Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, August 19th. BMO Capital Markets reissued a “market perform” rating and issued a $55.00 target price (up previously from $50.00) on shares of Novo Nordisk A/S in a research report on Tuesday, October 14th. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. Finally, Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 16th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Hold” and a consensus price target of $59.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.